Pharmafit Provence
OLIGOSOL Manganese Cobalt Oral solution in ampoule 28Amp/2ml

EA Pharma Laboratoire des Granions

OLIGOSOL Manganese Cobalt Oral solution in ampoule 28Amp/2ml

CIP / EAN code: 3400937547390

Product information from VIDAL.

Read the product information

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 15/07/2020

MANGANESE-COBALT OLIGOSOL, oral solution in ampoule


Forms and presentations

Oral solution.
Ampoule with two self-breaking tips of 2 ml. Box of 28.


Composition

For one ampoule of 2 ml:

Manganese gluconate: 0,590 mg
(Corresponding quantity of manganese: 0,0728 mg)

Cobalt gluconate: 0,553 mg
(Corresponding quantity of cobalt: 0,0726 mg)

Excipient with known effect: glucose (100 mg in one ampoule of 2 ml).


Excipients:

Anhydrous glucose, purified water.



Indications

Used as a terrain modifier, particularly during states of neurovegetative dystonia.



Dosage and administration

Dosage

FOR ADULTS ONLY.

1 to 2 ampoules per day.

The ampoules are to be taken:

  • preferably in the morning on an empty stomach,
  • possibly 15 minutes before a meal or in the evening at bedtime.

Method of administration

Oral use.

Sublingual administration is recommended: hold the contents of the ampoule under the tongue for 1 to 2 minutes before swallowing.



Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section Composition.



Warnings and precautions

This medicine contains glucose. Its use is not recommended in patients with glucose-galactose malabsorption syndrome.



Interactions

The data available to date do not suggest the existence of clinically significant interactions.



Fertility, pregnancy and breastfeeding

In the absence of experimental and clinical data, and as a precaution, use of this medicine should be avoided during pregnancy and breastfeeding.



Adverse effects

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr.



Overdose

No cases of overdose have been reported.



Pharmacodynamics

Pharmacotherapeutic class: OLIGOTHERAPY (V: various)

Trace mineral elements.



Shelf life

5 years.



Special storage precautions

Store at a temperature below 25 °C.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400937547390 (28 amp/2 mL).
Not reimbursed by Social Security.
 
Marketing authorisation holder: Labcatal, 1198 avenue Docteur Maurice Donat, Zac du Fond de l'Orme, 06250 Mougins.

GRANIONS EA-PHARMA Laboratory
Le Parador II
5, allée Crovetto-Frères. 98000 Monaco
Tel: 00 377 92 05 76 30

Source: VIDAL · Updated on 11/11/2026. This information does not replace advice from a healthcare professional.